Press Releases
Our team at Pharmafocuseurope.com believes that press releases are an important marketing tool for highlighting a client's corporate message and ensuring it reaches their target audience. The feature can be used to publish business agreements, annual reports, financial results, corporate performances, important announcements, and any other important information that needs to be communicated to the target audience. Pharma companies can also use it to launch new products and promote existing ones.
Moleculin Announces Commencement of NIH-Funded Phase 2 Clinical Trial of STAT3 Inhibitor for the Treatment of Glioblastoma (NU 21C06)
Thursday, May 16, 2024Moleculin Biotech Inc a clinicalstage pharmaceutical company with a broad portfolio of drug candidates targeting hardtotreat tumors and viruses today
CENTOGENE and Evotec Discover Promising New Molecule to Treat Gaucher Disease
Wednesday, May 15, 2024Centogene NV the essential life science partner for datadriven answers in rare and neurodegenerative diseases today announced the discovery of a new small molecule together with Evotec SE
Moffitt Cancer Center and Fulgent Pharma Join Forces to Revolutionize Cancer Therapeutics
Wednesday, May 15, 2024Moffitt Cancer Center a worldrenowned cancer treatment and research center and Fulgent Pharma a subsidiary of Fulgent Genetics Inc and a leading nanobiotechnology company specializing
AC Immune and Takeda Sign Exclusive Option and License Agreement for Active Immunotherapy Targeting Amyloid Beta for Alzheimer’s Disease
Tuesday, May 14, 2024Takeda and AC Immune SA today announced an exclusive worldwide option and license agreement for AC Immunes active immunotherapies targeting toxic
Reneo Pharmaceuticals and OnKure Announce Proposed Merger
Tuesday, May 14, 2024Reneo Pharmaceuticals Inc and OnKure Inc a privatelyheld clinicalstage biopharmaceutical company focused on the development of novel precision medicines in oncology today announced that they have entered
Intensity Therapeutics, Inc. and SAKK Collaborate on Phase 2 Trial for Breast Cancer Drug INT230-6 in Europe
Monday, May 13, 2024Intensity Therapeutics Inc a latestage clinical biotechnology company focused on the discovery and development of proprietary novel immunebased intratumoral cancer therapies designed to kill tumors and increase immune system
Oregon Therapeutics and Lantern Pharma Collaborate on AI-Optimized Drug Development for XCE853
Monday, May 13, 2024Oregon Therapeutics and Lantern Pharma Launch Strategic Artificial Intelligence Collaboration to Optimize Development of XCE a Potent Cancer Metabolism Inhibitor and FirstinClass Drug Candidate
Novavax and Sanofi Announce Co-exclusive Licensing Agreement to Co-commercialize COVID-19 Vaccine and Develop Novel COVID-19-Influenza Combination Vaccines
Saturday, May 11, 2024Novavax Inc a global company advancing proteinbased vaccines with its MatrixM adjuvant has entered into a coexclusive licensing agreement with Sanofi
FDA-approved TIVDAK®: Targeting Tissue Factor in Cervical Cancer
Friday, May 10, 2024US FDA granted full approval for Seagen Incs TIVDAK tisotumab vedotin targeting tissue factor TF for the treatment of patients with recurrent or metastatic cervical cancer who have progressed on or after chemotherapy This marks a significant advancem...
Sangamo Therapeutics Presents Next-Generation Modular Integrase Technology Engineered to Enable Large-Scale Genome Editing
Friday, May 10, 2024Sangamo Therapeutics Inc a genomic medicines company today presented preclinical data showcasing its novel nextgeneration integrase technology
